- Funding to support late stage development of a novel oral p300/CBP inhibitor, inobrodib for the treatment of multiple myeloma
- As part of its global team expansion, the company opened a new office just outside Boston in Burlington, MA
- Jasper Bos, PhD, General Partner, Forbion will join the CellCentric board
Naarden, The Netherlands, 19 May 2025 – CellCentric, a clinical-stage biotechnology company developing inobrodib, a first in class oral cancer drug to treat specific cancers, notably multiple myeloma, today announced the completion of a $120 million Series C funding round. The financing was co-led by Forbion and RA Capital Management, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital and impact investment arm.
The funding will further support the advancement of CellCentric's novel oral p300/CBP inhibitor, inobrodib, for the treatment of multiple myeloma. Despite significant recent progress in treating multiple myeloma, the majority of patients still succumb to the disease, creating a large unmet medical need. A large number of patients are not eligible for, or become resistant to, the latest therapies. Inobrodib’s truly novel mechanism of action, oral delivery, and favorable safety profile, make it an attractive additional option. It has the potential to become an agent used across multiple settings, with different combination agents.
A phase IIa dose optimisation clinical study is ongoing with an all-oral triplet of inobrodib combined with pomalidomide and dexamethasone. Proceeds from the Series C financing will be used to support multiple clinical studies in both earlier and later line settings.
CellCentric has developed an innovative and impactful therapy for multiple myeloma with inobrodib, a first-in-class oral p300/CBP inhibitor. This novel agent has demonstrated promising efficacy and a manageable safety profile in early clinical trials. We are enthusiastic about supporting CellCentric as it advances inobrodib into registration studies, aiming to transform multiple myeloma treatment across various stages of the disease.
Jasper Bos
PhD, General Partner at Forbion, who is joining the CellCentric Board
We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today's announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team.
Will West
CEO of CellCentric
In 2023, the FDA granted Fast Track and orphan drug designation to inobrodib for treating relapsed or refractory multiple myeloma. Last year, CellCentric released promising efficacy and safety data at the American Society of Hematology (ASH) Annual Meeting. This month, a new CellCentric office opened in Burlington MA, just outside Boston, as the company builds its team globally.